All In Biotech

Drug Trial Radar · NCT06468033

P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk

A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Study to Assess Efficacy and Safety of Ropeginterferon Alfa-2b (P1101) in Adult Patients With Pre-fibrotic/Early Primary Myelofibrosis (PMF) or Overt PMF at Low or Intermediate-1 Risk According to DIPSS Plus (HOPE-PMF): The Core Study and Its Extension Study

Last checked: Nov 20, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

160

Actual

Start

Jul 18, 2025

Primary completion

Nov 18, 2027

Study completion Jan 11, 2029

Sponsor

Lead sponsor
PharmaEssentiaIndustry
Sponsor type
Industry
First posted
Jun 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 3 double-blind clinical trial arm to test Ropeginterferon alfa-2b (P1101) in adult patients with Primary Myelofibrosis (PMF) at early stage or low to medium risk. Participants will receive the study drug/placebo bi-weekly and have an assessment visit every 4 weeks. The ratio of study drug to placebo group is 2:1.

Conditions

  • Primary Myelofibrosis
  • Myeloproliferative Neoplasm

Interventions

  • Ropeginterferon alfa-2bBiological

    Pre-filled Syringe. Dosage: up to 500mcg

  • PlaceboOther

    Placebo is a look-alike substance with the intervention (Ropeginterferon alfa-2b) that contains no active drug.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Platelet count equal or less (≤) 400 × 10^9/LTime frame: 80 weeks
  2. Number of Participants with White Blood Cells (WBC) count equal or less (≤) 10 × 10^9/LTime frame: 80 weeks
  3. Number of Participants with Hemoglobin (Hgb) equal or greater (≧) 10.0 g/dLTime frame: 80 weeks
  4. Number of Participants absence of major thrombotic eventsTime frame: 80 weeks
  5. Number of Participants with no progression to secondary acute myeloid leukemia (AML).Time frame: 80 weeks
  6. Number of Participants with no progression on the Total Symptom Score (TSS)Time frame: 80 weeks

Locations

73 sites in 9 countries. Site status is shown where the registry gives one.

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California

  • Georgetown University Medical Center

    Washington D.C., District of Columbia

  • University of Kansas Medical Center (KUMC)

    Kansas City, Kansas

  • American Oncology Partners of Maryland PA (Center for Cancer and Blood Disorders)

    Bethesda, Maryland

  • Washington University School of Medicine

    St Louis, Missouri

  • Weill Medical College of Cornell University

    New York, New York

  • Stony Brook University Medical Center

    Stony Brook, New York

  • Levine Cancer Institute

    Charlotte, North Carolina

  • Duke University

    Durham, North Carolina

  • Ohio State University

    Columbus, Ohio

  • MD Anderson Cancer Center

    Houston, Texas

  • Virginia Commonwealth University

    Richmond, Virginia

  • University of Washington Medical Center - Fred Hutchinson Cancer Center

    Seattle, Washington

  • St. Michael's Hospital

    Toronto, Ontario, Canada

  • Princess Margaret Hospital

    Toronto, Ontario, Canada

  • Jewish General Hospital

    Montreal, Quebec, Canada

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China

  • The Second Affiliated Hospital of AMU

    Chongqing, Chongqing Municipality, China

  • Southern Hospital of Southern Medical University

    Guangdong, Guangdong, China

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangzhou, China

  • Institute of Hematology and Oncology, Harbin The First Hospital

    Harbin, Heilongjiang, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Union Hospital Tong Ji Medical College

    Wuhan, Hubei, China

  • Jiangsu Provincial Hospital

    Nanjing, Jiangsu, China

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China

  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine

    Shanghai, Shanghai Municipality, China

  • Shanghai Sixth People's Hospital

    Shanghai, Shanghai Municipality, China

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China

  • Hematology Hospital of Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, China

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

  • Queen Mary Hospital

    Hong Kong, Hong Kong, Hong Kong

  • Kameda General Hospital

    Kamogawa, Chiba, Japan

  • Ehime University Hospital

    Matsuyama, Ehime, Japan

  • Hiroshima Red Cross & Atomic-Bomb Survivors Hospital

    Hiroshima, Hiroshima, Japan

  • Iwate Prefectural Central Hospital

    Morioka, Iwate, Japan

  • Shonan Kamakura General Hospital

    Kamakura, Kanagawa, Japan

  • Mie University Hospital

    Tsu, Mie-ken, Japan

  • University of Miyazaki Hospital

    Miyazaki, Miyazaki, Japan

Showing 40 of 73 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.